HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Mylan Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Mylan Intelligence Report

Generated from 7 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jul 6, 2026

Confidence

Moderate Confidence · 73%

Evidence

42 items

Sources

16

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Mylan maintains an active intelligence profile across Oncology, Bone Health, Hematology, Iron Deficiency Anemia, Pain Management. 7 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 73% across 3 tracked sources. Highest-priority development: FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Mylan Labs; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Notice: Register of authorised online sellers of medicines in Northern Ireland

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Investigational New Drug (IND) Application

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — ZOLEDRONIC ACID (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA Approves First Generic of Priftin (rifapentine) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 327 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Notice: Register of authorised online sellers of medicines in Northern Ireland

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ZOLEDRONIC ACID (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generic of Priftin (rifapentine) Tablets

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generic of Priftin (rifapentine) Tablets

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Additional Information on Transmucosal Immediate Release Fentanyl (TIRF) REMS

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves Ferric Carboxymaltose ANDA212572 by Mylan Labs

    Hematology · Iron Deficiency Anemia

  • FDA Grants Approval for Mylan's Liraglutide ANDA213155

    Endocrinology · GLP-1 Agonist

  • FDA Approves ANDA217769 for Ferric Carboxymaltose by Mylan

    Hematology · Iron Deficiency Anemia

  • FDA Approval Update for Divalproex Sodium by Mylan

    Neurology · Antiepileptic

  • FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

    Oncology · Bone Health

  • FDA Approves Supplement for Estradiol by Mylan Technologies

    Endocrinology · Hormone Replacement Therapy

  • FDA Grants AP Status for Mylan's Fentanyl Supplement

    Pain Management · Opioid

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.